Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers apoptosis in multiple myeloma (MM) cells; and importantly, is distinct from bortezomib (Velcade  TM ) to improve patient outcome in MM.
Abstract
Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers apoptosis in multiple myeloma (MM) to improve patient outcome in MM.
Introduction
Normal cellular homeostasis requires balanced regulation of protein synthesis and degradation. Intracellular protein degradation occurs majorly via a multi-subunit complex called the proteasome [1] [2] [3] [4] . Earlier studies by Ciechanover, Hershko and Rose et al., demonstrated that ATP-dependent conjugation of proteins with polypeptide (ubiquitin) mediates protein degradation. [5] [6] [7] [8] [9] [10] [11] The 26S multi-subunit proteasome complex [12] [13] [14] [15] containing 19S
units flanking a barrel-shaped 20S proteasome core [16] [17] [18] . The 19S units of the 26S proteasome complex regulate entry of ubiquitinated proteins into the 20S core chamber [2, 19, 20] . Protein ubiquitination is facilitated through several enzymatic reactions involving E1 and E2 ubiquitin enzymes as well as E3 ubiquitin ligase. [21, 22] Once the ubiquitinated proteins are recognized by the 19S regulatory subunits of the proteasome complex, they are degraded into small peptides by three major proteasomal activities residing within the 20S core complex i.e., [23] [24] [25] [26] .
chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-
Proteasomes regulate many normal cellular processes, such as cell cycle, inflammation, transcription, DNA replication, and apoptosis via proteolysis of key enzymes and regulatory proteins.
Deregulation of the Ubiquitin-Proteasome Signaling (UPS) [27] pathway is linked to the pathogenesis of various human diseases, [4, 28, 29] and therefore proteasome inhibitors offer great promise as therapeutic agents.
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The dipeptidyl boronic acid bortezomib/PS-341 (Velcade  TM ) is a reversible inhibitor of CT-L [30] exhibited remarkable anti-tumor activity against the 60 NCI tumor cell line panel. Bortezomib is the first in class proteasome inhibitor, approved by FDA for the treatment of relapsed and relapsed/refractory MM and Mantle cell lymphoma. [4, [31] [32] [33] Even though bortezomib therapy is a major advance (43% objective response rates) [32, 33] , it has been associated with possible off-target toxicities and the development of drug-resistance.
[ [34] [35] [36] [37] [38] Our recent study [39] characterized a novel proteasome inhibitor NPI-0052, a small molecule derived from the fermentation of a marine gram-positive actinomycete Salinospora tropica.
[40]
NPI-0052 induces apoptosis in MM cells resistant to conventional and bortezomib therapies, without significantly affecting normal lymphocyte viability.
[39]
Importantly, NPI-0052 is distinct from bortezomib in its chemical structure, effects on proteasome inhibition profiles and mechanisms of action.
For example, biochemical and genetic studies showed that NPI-0052, in contrast to bortezomib, relies more on FADD-caspase-8-mediated cell death signaling in MM cells. In vivo studies using human MM-xenografts show that NPI-0052 is well tolerated, prolongs survival, and reduces tumor recurrence.
Similar anti-tumor activity of NPI-0052 has been reported in CLL and colon cancer cells. [41, 42] Our preclinical data provided the basis for the ongoing phase-I clinical trial of NPI-0052 in relapsed/refractory MM patients.
For personal use only. on . by guest www.bloodjournal.org From 5 A recent series of elegant studies using an in vitro protein model system demonstrate that simultaneous inhibition of multiple proteasome activities is a prerequisite for significant (i.e., > 50%) proteolysis. [25] Moreover, MM and leukemia cell lines exhibit a differential pattern of qualitative and quantitative constitutive proteasome activity [43, 44] , suggesting a differential requirement to inhibit proteasome activity. Our prior study showed that bortezomib predominantly inhibits proteasome CT-L and more recently defined C-L activities.
A recent study showed that the epoxyketone-based irreversible proteasome inhibitor PR-171, like bortezomib, predominantly blocks CT-L activity.
[45]
Importantly, NPI-0052 blocks all three i.e., CT-L, T-L, and C-L proteasome activities.
It is therefore likely that NPI-0052, by virtue of its ability to block all three proteasome activities, can be combined with bortezomib or PR-171 to confer a broader proteasome inhibition at lower and potentially, safer doses. These findings provide the rationale for combining NPI-0052 with bortezomib to achieve optimal proteasome inhibition and potent anti-tumor activity, while allowing for the use of lower doses of bortezomib to reduced toxicity.
In the present study, we characterized the effects of NPI- 
Material and Methods
Cell culture MM.1S {Dexamethasone-(Dex) sensitive}, MM.1R (Dex-resistant), RPMI-8226, Doxorubicin (Dox)-resistant (Dox-40), U266, OPM2 and INA6-6 (IL-6-dependent) human MM cell lines were maintained as previously described. [39] MM cells were freshly isolated from patients relapsing after multiple prior therapies including Dex, Melphalan, Thalidomide or bortezomib. Tumor cells were purified by CD138 positive selection [46] using the Auto MACS magnetic cell sorter (Miltenyi Biotec Inc., Auburn, CA).
Informed consent was obtained from all patients in accordance with the Helsinki protocol. Cells were treated with NPI-0052 (Nereus Pharmaceuticals, Inc., San Diego, CA), and bortezomib (Millennium Pharmaceuticals, Cambridge, MA). PBMNCs from normal healthy donors were maintained in culture medium.
Cell viability and apoptosis assays Cell viability was assessed by 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Chemicon International Inc., Temecula, CA) assay, as previously described.
[46]
Cell death was quantified using 'Live and dead cell assay' (Molecular Probes, Carlsbad, CA).
Briefly, 1 x 10 6 cells were treated with NPI-0052 (1 nM), bortezomib (3 nM) or their combination; stained with ethidium homodimer and calcein-AM; and then analyzed under a fluorescence microscope. Annexin V/Propidium iodide (PI) staining assays were
For personal use only. on . by guest www.bloodjournal.org From 7 performed as previously described. [46] TUNEL apoptosis detection kit (Upstate/Millipore, Billerica, MA) was utilized to measure apoptosis in murine tumor sections.
In vitro migration and capillary-like tube structure formation assays Migration was assessed by Transwell Boyden chamber (Chemicon, Billerica, MA), as previously described. [47, 48] In vitro angiogenesis was determined by Matrigel capillary-like tube structure formation assay. [47] Western blotting Immunoblot analysis was performed using antibodies to Caspase-8, Caspase-9, Caspase-3 (Cell Signaling, In vitro and in vivo proteasome activity assays 20S proteasome activity assays were performed using fluorogenic peptide substrates, as previously described. [39, 49] In vivo comparative analysis of proteasome activities was performed in tumors from treated mice. Ninety minutes after administration of drugs, the animals were anesthetized and tumors were excised, followed by determination of ex vivo proteasome activity, as detailed above.
Human plasmacytoma xenograft model All animal studies were approved by DFCI Institutional Animal Care and Use Committee. The xenograft tumor model was performed as previously described. [39, 50] CB-17 SCID-mice (n = 24) (Taconic, Gemantown, NY) were subcutaneously inoculated with 5.0 x 10 6 MM.1S cells in 100 µl of (Fig 1A-1G ). Isobologram analysis [52] confirmed that combined NPI-0052 + bortezomib triggered synergistic anti-MM activity in MM cell lines, albeit with differential kinetics. The combination ratio of agents varied for each cell line to achieve a similar degree of cell death. 24 nM) and 1 nM bortezomib (IC 50 : 30 nM) triggers 43% growth inhibition, whereas no significant growth inhibition was observed using either of these agents alone at these low concentrations For personal use only. on . by guest www.bloodjournal.org From (Fig 1B) . These data confirm and extend our prior findings demonstrating synergistic anti-MM activity of NPI-0052 + bortezomib.
We next examined whether NPI-0052 + bortezomib-induced decrease in viability is due to apoptosis. Combined NPI-0052 + bortezomib, but not either agent alone, triggered significant apoptosis in MM.1S cells, as determined by Annexin V/PI staining assays. (P < 0.05, n=3) (Fig 1H) . [53,54] The effect of NPI-0052 + bortezomib was examined on these events using Transwell insert systems and in (Fig 4A) .
Importantly, pretreatment of MM.1S cells with the pan-caspase inhibitor (z-VAD-fmk) significantly blocked NPI-0052 + bortezomib-induced apoptosis (P < 0.05, n = 3) (Fig 4B) .
Prior studies have established that BH3-only Bcl-2 family
For personal use only. on . by guest www.bloodjournal.org From protein BIM regulates caspase-9 activation by modulating Cytoc/Smac release from mitochondria to the cytosol. [55] Our data show that combined NPI-0052 + bortezomib, but not either agent alone, significantly upregulates BIM protein levels (3 fold increase) without altering Bcl-2 protein levels (Fig 4C) . To determine whether BIM mediates NPI-0052 + bortezomib-induced apoptosis, we knocked down BIM expression using siRNA strategy.
The functional specificity of BIM siRNA was evident from a marked decrease in protein levels of all three isoforms of BIM (Fig 4D) .
Importantly, transfection of siRNA BIM, but not negative-control (scrambled) siRNA, significantly inhibits NPI-0052 + bortezomibinduced apoptosis in MM.1S cells (Fig 4E) . These findings suggest that NPI-0052 + bortezomib-triggered apoptosis is mediated, at least in part, via BIM. [29, [59] [60] [61] We asked whether combined low doses of NPI-0052 and bortezomib similarly induce UPR. Our results show that even at low doses, the combination of NPI-0052 and bortezomib retained its ability to induce ER-stress response, evidenced by increased eIf2-α kinase activity and protein levels of its target protein CHOP/GADD153 (Fig 5B) .
Multiple prior studies link bortezomib-induced apoptosis with the upregulation of heat shock proteins (Hsp's). 
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Hsp-90 or Hsp-27. The lack of Hsp-90 or Hsp-27 induction may be due to differential signaling pathways triggered by a higher dose of bortezomib alone versus its combination with NPI-0052.
Furthermore, NPI-0052 + bortezomib-induced ER stress response (as shown in Fig 5B) and apoptosis likely involves Hsp-70, but not Hsp-27 and Hsp-90. These findings provide evidence of distinct mechanism of action of combined NPI-0052 + bortezomib versus each agent alone. Our findings have clinical implications: Hsp's confer drug resistance, and prior studies showed that higher concentrations of bortezomib induce all three Hsp's [29, 62] . Based on these findings, bortezomib has been combined with Hsp-90 inhibitor in clinical trials to overcome Hsp-mediated drug resistance. Our present finding that combined low dose bortezomib with NPI-0052 does not induce two of the three Hsp's, suggests that drug resistance may be less frequent in patients given combined low dose regimens.
We and others have shown that proteasome inhibitors block NF-κB, a major growth and survival pathway in MM cells.
[39, [63] [64] [65] Combined low doses of NPI-0052 (1 nM) and bortezomib (3 nM), but not either agent alone, showed synergistic inhibition of NF-κB activity, evidenced by decrease in nuclear translocation of p65 subunit (CI = 0.35; n =3) (Fig 5D) .
Effects of NPI-0052 + bortezomib on CT-L, C-L and T-L proteolytic activities Although proteasome inhibitors induce apoptotic signaling cascades, the primary target of these agents is the proteasome. The proteolytic activity of proteasomes is mediated by three active sites: CT-L, T-L and C-L. [23] [24] [25] [26] 29, 66] Our 
there was a significant (75%) reduction (P = 0.03) in tumor growth relative to untreated mice (Fig 6A and inset) . As an additional control, we also treated mice with MTD of NPI-0052 and bortezomib (0.15 mg/kg and 1 mg/kg, respectively). As in our previous study, [39] (Fig 6B) . Similarly, NPI-0052 + bortezomib triggered robust caspase activation in tumors ( Fig   6C) . In agreement with these data, a significant decrease in Ki- (Fig 6D) .
In vitro data indicate anti-angiogenic activity of NPI-0052 + bortezomib, and we therefore next evaluated paraffin-embedded sections of xenografted tumors harvested from mice treated with NPI-0052 and bortezomib for Factor VIII staining, a marker of angiogenesis. As seen in Fig 7A low 
Discussion
Our preclinical and clinical studies led to the FDA approval of bortezomib (Velcade TM ) for the treatment of relapsed and relapsed/refractory MM. [32, 33, 67, 68] However, as with other agents, dose-limiting toxicities and the development of resistance limits its long term utility. [34] [35] [36] [37] [38] Our recent study showed another novel proteasome inhibitor NPI-0052 to also have anti-MM cytotoxicity.
NPI-0052 is currently being evaluated in MM patients in a phase-I clinical trial. Here, we examined whether two proteasome inhibitors that are distinct in their chemical structure, mechanisms of action, and effects on proteasomal activities, can be combined at low doses to enhance anti-MM activity, reduce toxicity, and overcome drug resistance.
We first show that the combination of low doses of NPI-0052
and bortezomib induces apoptosis even in MM cells resistant to conventional and bortezomib therapies, without affecting normal (Fig 2A) , confirm that MM cells are more sensitive to proteasome inhibition than normal cells.
Interestingly, while only NPI-0052 is known to inhibit T-L activity, its combination with bortezomib blocks T-L activity even higher. In this context, prior studies have reported that proteasome active sites allosterically regulate each other [69, 70] For example, a biochemical study showed that occupancy of C-L sites induces the T-L activity of proteasomes. [69] It is likely that blockade of one proteasomal activity may affect the function of other proteasomal activity. While a definitive evidence for 
